U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H11NO
Molecular Weight 185.2223
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIRFENIDONE

SMILES

Cc1ccc(=O)n(c1)-c2ccccc2

InChI

InChIKey=ISWRGOKTTBVCFA-UHFFFAOYSA-N
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

HIDE SMILES / InChI
Molecular Formula C12H11NO
Molecular Weight 185.2223
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=12010989; http://www.ncbi.nlm.nih.gov/pubmed/?term=9435445; https://en.wikipedia.org/wiki/Pirfenidone

Pirfenidone is a synthetic antifibrotic agent indicated for the treatment of idiopathic pulmonary fibrosis as Esbriet. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors. It also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. Pirfenidone has demonstrated activity in multiple fibrotic conditions however the exact mechanism of action of pirfenidone in the treatment of IPF has not been established.

CNS Activity

Originator

Approval Year

2014
439
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8043
ESBRIET

Approved Use

Indicated for the treatment of idiopathic pulmonary fibrosis

Launch Date

1.42611841E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6560 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/28808905
801 mg single, oral
dose: 801 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PIRFENIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
98000 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/28808905
801 mg single, oral
dose: 801 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PIRFENIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.75 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/28808905
801 mg single, oral
dose: 801 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PIRFENIDONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
3 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
PIRFENIDONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
42%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
PIRFENIDONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Disc. AE: Rash, Nausea...
AEs leading to
discontinuation/dose reduction:
Rash (1.3%)
Nausea (1.1%)
Rash (3%)
Nausea (3%)
Diarrhea (3%)
Photosensitivity reaction (3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Disc. AE: Weight decreased, Photosensitivity reaction...
AEs leading to
discontinuation/dose reduction:
Weight decreased (0.8%)
Photosensitivity reaction (0.6%)
Respiratory failure (0.5%)
Hepatic enzyme increased (0.5%)
Bladder cancer (0.5%)
Vomiting (0.3%)
GERD (0.3%)
Malaise (0.3%)
Dysgeusia (0.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
AEs

AEs

AESignificanceDosePopulation
Nausea 1.1%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Rash 1.3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Diarrhea 3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Nausea 3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Photosensitivity reaction 3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Rash 3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf
Dysgeusia 0.3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
GERD 0.3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Malaise 0.3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Vomiting 0.3%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Bladder cancer 0.5%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Hepatic enzyme increased 0.5%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Respiratory failure 0.5%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Photosensitivity reaction 0.6%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Weight decreased 0.8%
Disc. AE
2403 mg 1 times / day steady, oral
Recommended
Dose: 2403 mg, 1 times / day
Route: oral
Route: steady
Dose: 2403 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
unhealthy, 67 years (range: 40 - 80 years)
n = 623
Health Status: unhealthy
Condition: idiopathic pulmonary fibrosis
Age Group: 67 years (range: 40 - 80 years)
Sex: M+F
Population Size: 623
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf
Page: p. 23
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1467

inducer
707
substrate
936

inhibitor
1604

inducer
355
substrate
1118

inhibitor
1702

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1383

CYP2A6
627

CYP2C19
1325

CYP2E1
790

CYP2C8
818

CYP3A4/5
241

P-gp
1330
CYP1A2
972

CYP1A1
325

CYP2A6
485

CYP2B6
616

CYP2C8
634

CYP2C18
135

CYP2C19
910

CYP2E1
606

CYP2J2
53

P-gp
1400
CYP3A
118

CYP2C19
269

CYP3A4/5
108

CYP1A2
637
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1532
 no
5-carboxy-pirfenidone
1
CYP1A2
1532
 no
5-carboxy-pirfenidone
1
CYP2A6
659
 no
5-carboxy-pirfenidone
1
CYP2C19
1392
 no
5-carboxy-pirfenidone
1
CYP2C19
1392
 no
5-carboxy-pirfenidone
1
CYP2C8
865
 no
5-carboxy-pirfenidone
1
CYP2C9
1648
 no
CYP2C9
1648
 no
5-carboxy-pirfenidone
1
CYP2C9
1648
 no
5-carboxy-pirfenidone
1
CYP2D6
1738
 no
5-carboxy-pirfenidone
1
CYP2E1
871
 no
5-carboxy-pirfenidone
1
CYP3A4
1772
 no
5-carboxy-pirfenidone
1
CYP3A4/5
293
 no
CYP3A4/5
293
 no
5-carboxy-pirfenidone
1
P-gp
1514
 weak [IC50 >1000 uM]
CYP1A2
1532
 yes [Inhibition 1000 uM]
CYP2A6
659
 yes [Inhibition 1000 uM]
CYP2C19
1392
 yes [Inhibition 1000 uM]
CYP2C9
1648
 yes [Inhibition 1000 uM]
CYP2D6
1738
 yes [Inhibition 1000 uM]
CYP2E1
871
 yes [Inhibition 1000 uM]
CYP3A4
1772
 yes [Inhibition 1000 uM]
CYP2C19
1392
 yes
CYP3A
271
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
972
 major
yes (co-administration study)
Comment: In a single-dose drug interaction study in 25 healthy nonsmokers and 25 smokers, ESBRIET was coadministered with fluvoxamine (50 mg at bedtime for 3 days; 50 mg twice a day for 3 days, and 50 mg in the morning and 100 mg at bedtime for 4 days). An approximately 4-fold increase in exposure to pirfenidone in nonsmokers and approximately 7-fold increase in exposure in smokers was observed.
Page: 6.0
CYP1A1
325
 yes
CYP2A6
485
 yes
CYP2B6
616
 yes
CYP2C18
135
 yes
CYP2C19
910
 yes
CYP2C8
634
 yes
CYP2C9
936
 yes
CYP2D6
1118
 yes
CYP2E1
606
 yes
CYP2J2
53
 yes
P-gp
1400
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:32016
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:32016
ChemicalBook
CB5299210
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5299210
MolPort
MolPort-003-666-737
https://www.molport.com/shop/molecule-link/MolPort-003-666-737
Selleck Chemicals
pirfenidone
http://www.selleckchem.com/products/pirfenidone.html
ZINC
ZINC000000001958
http://zinc15.docking.org/substances/ZINC000000001958
eMolecules
593320
https://www.emolecules.com/cgi-bin/more?vid=593320
PubMed

PubMed

TitleDatePubMed
Modulation of articular chondrocyte activity by pirfenidone.
2003
Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.
2004 Aug
Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.
2004 Dec
Pirfenidone.
2004 Feb
Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis.
2004 Jul
Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.
2004 Jul-Aug
Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model.
2004 Mar 15
Gateways to clinical trials.
2004 May
Potential nonhormonal therapeutics for medical treatment of leiomyomas.
2004 May
The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2.
2004 Nov
Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes.
2004 Nov
Pharmacokinetics of orally administered pirfenidone in male and female beagles.
2004 Oct
Effect of pirfenidone on induction of chemokines in rat hepatocytes.
2004 Sep
Effects of pirfenidone on endotoxin-induced liver injury after partial hepatectomy in rats.
2004 Sep
Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats.
2004 Sep
Primary progressive multiple sclerosis : current and future treatment options.
2005
Protection of pirfenidone against an early phase of oleic acid-induced acute lung injury in rats.
2005 Apr
Retardation of kidney failure -- applying principles to practice.
2005 Jan
Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats.
2005 Jan
The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model.
2005 Jan-Feb
[Drug treatments for idiopathic pulmonary fibrosis].
2005 Jun
Treatment of idiopathic pulmonary fibrosis: is there anything new?
2005 Jun
Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway.
2005 Jun
Expression of HSP47 in usual interstitial pneumonia and nonspecific interstitial pneumonia.
2005 Jun 14
[Interstitial pneumonia].
2005 May
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
2005 May 1
Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation.
2005 Nov
The questionable efficacy of pirfenidone in IPF.
2005 Nov 1
Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.
2005 Nov 1
Sequential testing for efficacy in clinical trials with non-transient effects.
2005 Nov 15
Gateways to clinical trials.
2005 Oct
Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts.
2005 Oct
Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model.
2005 Sep
Symptomatic and disease-modifying therapies for multiple sclerosis: recent developments: highlights of the 9th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, October 3, 2004, Toronto, Ontario, Canada.
2005 Winter
Pulmonary fibrosis in hermansky-pudlak syndrome. a case report and review.
2006
Pirfenidone and chronic progressive obliterative airway disease.
2006 Apr
[Pulmonary fibrosis--a therapeutic dilemma?].
2006 Apr 15
Simple determination of pirfenidone in rat plasma via high-performance liquid chromatography.
2006 Dec
EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts.
2006 Jan 27
Promising pharmacologic innovations in treating pulmonary fibrosis.
2006 Jun
[Newly developed therapeutic drugs for idiopathic interstitial pneumonias].
2006 Jun 10
Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach.
2006 Mar
Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.
2006 May 1
A pilot study in patients with established advanced liver fibrosis using pirfenidone.
2006 Nov
Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure.
2006 Oct 17
Long-term administration of pirfenidone improves cardiac function in mdx mice.
2006 Sep
Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge.
2006 Sep
Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma.
2007
A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone.
2007 Feb
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
2011 May 21
Patents

Patents

JP2010120912A
1
US6211209
1
US6261537
10
US6264917
2
US6300349
1
US6323236
10
US6331289
5

Sample Use Guides

In Vivo Use Guide
The recommended daily maintenance dosage is 801 mg (three 267 mg capsules) three times a day with food for a total of 2403 mg/day. Doses should be taken at the same time each day. Upon initiation of treatment, titrate to the full dosage of nine capsules per day over a 14-day period as follows: 1 capsule three times days 1 through 7; 2 capsules three times a day days 8 through 14; 3 capsules three times a day days 15 onward.
Route of Administration: Oral
In Vitro Use Guide
0.01, 0.1, 0.3, and 1.0 mg/mL in in cultured myometrial and leiomyoma smooth muscle cells.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:07:05 UTC 2021
Edited
by admin
on Fri Jun 25 21:07:05 UTC 2021
Record UNII
D7NLD2JX7U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIRFENIDONE
DASH   EMA EPAR   INN   JAN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
5-METHYL-1-PHENYL-2(1H)-PYRIDONE
Systematic Name English
PIRFENIDONE [USAN]
Common Name English
PIRFENIDONE [MART.]
Common Name English
2(1H)-PYRIDINONE, 5-METHYL-1-PHENYL-
Systematic Name English
PIRFENIDONE [EMA EPAR]
Common Name English
PIRFENIDONE [EP MONOGRAPH]
Common Name English
PIRFENIDONE [JAN]
Common Name English
PIRFENIDONE COMPONENT OF ESBRIET
Brand Name English
PIRFENIDONE [ORANGE BOOK]
Common Name English
PIRFENIDONE [INN]
Common Name English
ESBRIET
Brand Name English
ESBRIET COMPONENT PIRFENIDONE
Brand Name English
PIRFENIDONE [VANDF]
Common Name English
PIRFENIDONE [MI]
Common Name English
AMR-69
Code English
PIRFENIDONE [WHO-DD]
Common Name English
PIRESPA
Brand Name English
NSC-748456
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 727219
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
EU-Orphan Drug EU/3/04/241
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
FDA ORPHAN DRUG 436914
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
EMA ASSESSMENT REPORTS ESBRIET (AUTHORISED: IDIOPATHIC PULMONARY FIBROSIS)
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
NDF-RT N0000191420
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
NCI_THESAURUS C257
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
NCI_THESAURUS C797
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
WHO-ATC L04AX05
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
FDA ORPHAN DRUG 177903
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
WHO-VATC QL04AX05
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
FDA ORPHAN DRUG 411113
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C2635
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
FDA UNII
D7NLD2JX7U
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
DRUG CENTRAL
4224
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
INN
3825
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
ChEMBL
CHEMBL1256391
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
IUPHAR
7532
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
MERCK INDEX
M8876
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
PIRFENIDONE
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
PUBCHEM
40632
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
MESH
C093844
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
EPA CompTox
53179-13-8
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
HSDB
8340
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
RXCUI
1592254
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY RxNorm
EVMPD
SUB09907MIG
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
CAS
53179-13-8
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
NDF-RT
N0000007575
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY Pyridones [Chemical/Ingredient]
DRUG BANK
DB04951
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY
JAPANESE REVIEW
PIRESPA
Created by admin on Fri Jun 25 21:07:06 UTC 2021 , Edited by admin on Fri Jun 25 21:07:06 UTC 2021
PRIMARY APPROVED OCTOBER 2008
Related Record Type Details
Structure of DEUPIRFENIDONE
LABELED -> NON-LABELED
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
MAJOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Related Record Type Details
Structure of 5-CARBOXY-PIRFENIDONE
METABOLITE INACTIVE -> PARENT
In vitro profiling studies in hepatocytes and liver microsomes have shown that ESBRIET is primarily metabolized in the liver by CYP1A2 and multiple other CYPs (CYP2C9, 2C19, 2D6, and 2E1).
MAJOR
PLASMA; URINE
Related Record Type Details
Structure of PIRFENIDONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC MULTIPLE DOSE ADMINISTRATION

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

Tmax PHARMACOKINETIC FED CONDITION

HIGH-FAT MEAL

Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966